Skip to main content

Advertisement

Springer Nature Link
Log in

Topical Corticosteroid-Induced Skin Atrophy: A Comprehensive Review

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Skin atrophy is an adverse effect of topical corticosteroids (TCs) which, as an established non-life-threatening effect, has been poorly reported by trials involving these drugs. Atopic dermatitis and psoriasis are example of disorders that require repeated therapies with TCs; however, assessing the atrophogenic activity of TCs is still an issue. This study aims to review clinical data on skin atrophy induced by TCs. Searches of the PubMed, EMBASE, and Cochrane (Central) databases from 1965 to May 2013 were undertaken using the keywords ‘corticosteroid’, ‘skin’, and ‘atrophy’. Skin and epidermal thickness values were retrieved from trials on healthy skin, and studies including skin atrophy as a safety endpoint in trials testing the efficacy of TCs were analyzed. Overall, 60 articles were retrieved. Whole skin and epidermal thickness were relevant parameters to measure early skin atrophy on healthy skin before it becomes clinically obvious. Epidermis thickness also seems to be more sensitive than whole skin thickness in detecting early atrophy; however, measuring skin atrophy still requires standardization. Further clinical trials on the atrophic effects of each TC are required to better evaluate their respective atrophic risks and their risk/benefit ratios. However, measuring epidermal or whole skin thickness will not be relevant in acute phases of inflammatory skin disorders treated with TCs because of the thickening induced by inflammation. In addition, skin atrophy seems to be induced by chronic TC use rather than by acute treatments. Long-term safety studies may be more relevant to evaluate atrophic activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–20.

    Article  CAS  PubMed  Google Scholar 

  2. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101–2.

    Article  CAS  PubMed  Google Scholar 

  3. Arkwright PD, Motala C, Subramanian H, Spergel J, Schneider LC, Wollenberg A. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1(2):142–51.

    Article  PubMed  Google Scholar 

  4. Svensson A, Chambers C, Ganemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27(7):1395–406.

    Article  CAS  PubMed  Google Scholar 

  5. Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther. 2009;16(3):264–73.

    Article  PubMed  Google Scholar 

  6. Sparkes CG, Wilson L. The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial. Br J Dermatol. 1974;90(2):197–203.

    Article  CAS  PubMed  Google Scholar 

  7. Groeneweg FL, Karst H, de Kloet ER, Joels M. Rapid non-genomic effects of corticosteroids and their role in the central stress response. J Endocrinol. 2011;209(2):153–67.

    Article  CAS  PubMed  Google Scholar 

  8. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163(1):29–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Baer RL, Myrow R. Complications of topical corticosteroid therapy. Arch Belg Dermatol Syphiligr. 1970;26(2):129–44.

    CAS  PubMed  Google Scholar 

  10. Stevanovic DV. Corticosteroid-induced atrophy of the skin with telangiectasia. A clinical and experimental study. Br J Dermatol. 1972;87(6):548–56.

    Article  CAS  PubMed  Google Scholar 

  11. Goette DK. Dermatrophy from long-term occulsive topical corticosteroid therapy. S Med J. 1973;66(5):542–6.

    Article  CAS  Google Scholar 

  12. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43.

    Article  CAS  PubMed  Google Scholar 

  13. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15 (quiz 6–8).

    Article  PubMed  Google Scholar 

  14. Guillot B. Glucocorticoid-induced cutaneous adverse events [in French]. Rev Med Interne. 2013;34(5):310–4.

    Article  CAS  PubMed  Google Scholar 

  15. Gebhardt C, Averbeck M, Diedenhofen N, Willenberg A, Anderegg U, Sleeman JP, et al. Dermal hyaluronan is rapidly reduced by topical treatment with glucocorticoids. J Invest Dermatol. 2010;130(1):141–9.

    Article  CAS  PubMed  Google Scholar 

  16. Haapasaari KM, Risteli J, Karvonen J, Oikarinen A. Effect of hydrocortisone, methylprednisolone aceponate and momethasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol. 1997;10(5–6):261–4.

    Article  CAS  PubMed  Google Scholar 

  17. Barnes L, Ino F, Jaunin F, Saurat JH, Kaya G. Inhibition of putative hyalurosome platform in keratinocytes as a mechanism for corticosteroid-induced epidermal atrophy. J Invest Dermatol. 2013;133(4):1017–26.

    Article  CAS  PubMed  Google Scholar 

  18. Mengeaud V, Dautezac-Vieu C, Josse G, Vellas B, Schmitt AM. Prevalence of dermatoporosis in elderly French hospital in-patients: a cross-sectional study. Br J Dermatol. 2012;166(2):442–3.

    Article  CAS  PubMed  Google Scholar 

  19. Kaya G, Saurat JH. Dermatoporosis: a chronic cutaneous insufficiency/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. Dermatology. 2007;215(4):284–94.

    Article  PubMed  Google Scholar 

  20. Saurat JH. Dermatoporosis. The functional side of skin aging. Dermatology. 2007;215(4):271–2.

    Article  PubMed  Google Scholar 

  21. Dölle S, Hoser D, Rasche C, Loddenkemper C, Maurer M, Zuberbier T, et al. Long-term reduction in local inflammation by a lipid raft molecule in atopic dermatitis. Allergy. 2010;65(9):1158–65.

    PubMed  Google Scholar 

  22. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;123(5):1124–33.

    Article  CAS  PubMed  Google Scholar 

  23. Kyllonen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150(6):1174–81.

    Article  CAS  PubMed  Google Scholar 

  24. Polano MK, van der Rhee HJ, van der Schroeff JG. A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically. Acta Derm Venereol. 1982;62(4):361–4.

    CAS  PubMed  Google Scholar 

  25. van der Vleuten CJ, van Vlijmen-Willems IM, de Jong EM, van de Kerkhof PC. Clobetasol-17 propionate lotion under hydrocolloid dressing (duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Arch Dermatol Res. 1999;291(7–8):390–5.

    Article  PubMed  Google Scholar 

  26. Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05 % add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009;84(4 Suppl):25–32.

    PubMed  Google Scholar 

  27. Yazdanparast P, Carlsson B, Oikarinen A, Risteli J, Lavin T, Faergemann J. Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans. Thyroid. 2006;16(11):1157–62.

    Article  CAS  PubMed  Google Scholar 

  28. Uliasz A, Zeichner J, Soung J, Wong V, Lebwohl M. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1 % versus clobetasol propionate cream 0.05 % in participants with corticosteroid-responsive dermatoses. Cutis. 2008;81(6):517–9.

    PubMed  Google Scholar 

  29. Gans EH, Sadiq I, Stoudemayer T, Stoudemayer M, Kligman AM. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1 % cream compared with clobetasol propionate 0.05 % cream and foam, and a vehicle. J Drugs Dermatol. 2008;7(1):28–32.

    PubMed  Google Scholar 

  30. Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH. Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol. 2002;15(2):85–91.

    Article  CAS  PubMed  Google Scholar 

  31. Hoffmann K, Auer T, Stucker M, Hoffmann A, Altmeyer P. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol. 1998;10(2):137–42.

    Article  CAS  PubMed  Google Scholar 

  32. Dykes PJ, Marks R, Hill S, Mills C, Eastwood R. The kinetics of skin thinning induced by topical fluticasone propionate 0.05 % cream in volunteer subjects. Clin Exp Dermatol. 1996;21(3):180–4.

    Article  CAS  PubMed  Google Scholar 

  33. Lubach D, Rath J, Kietzmann M. Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. Dermatology. 1995;190(1):51–5.

    Article  CAS  PubMed  Google Scholar 

  34. Levy J, Gassmuller J, Schroder G, Audring H, Sonnichsen N. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness. Skin Pharmacol. 1994;7(4):231–6.

    Article  CAS  PubMed  Google Scholar 

  35. Lubach D, Rath J, Kietzmann M. Steroid-induced dermal thinning: discontinuous application of clobetasol-17-propionate ointment. Dermatology. 1992;185(1):44–8.

    Article  CAS  PubMed  Google Scholar 

  36. Serup J, Holm P. Domoprednate (Stermonid®), a topical D-homocorticosteroid, skin atrophy and telangiectasia: a double-blind randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasol propionate and placebo. Dermatologica. 1985;170(4):189–94.

    Article  CAS  PubMed  Google Scholar 

  37. Somerma S, Lassus A, Salde L. Assessment of atrophy of human skin caused by corticosteroids using chamber occlusion and suction blister techniques. Acta Derm Venereol. 1984;64(1):41–5.

    CAS  PubMed  Google Scholar 

  38. Jablonska S, Groniowska M, Dabroswki J. Comparative evaluation of skin atrophy in man induced by topical corticoids. Br J Dermatol. 1979;100(2):193–206.

    Article  CAS  PubMed  Google Scholar 

  39. El Madani HA, Tancrede-Bohin E, Bensussan A, Colonna A, Dupuy A, Bagot M, et al. In vivo multiphoton imaging of human skin: assessment of topical corticosteroid-induced epidermis atrophy and depigmentation. J Biomed Opt. 2012;17(2):026009.

    Article  PubMed  Google Scholar 

  40. Josse G, Rouvrais C, Mas A, Haftek M, Delalleau A, Ferraq Y, et al. A multitechnique evaluation of topical corticosteroid treatment. Skin Res Technol. 2009;15(1):35–9.

    Article  CAS  PubMed  Google Scholar 

  41. Cossmann M, Welzel J. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial. Br J Dermatol. 2006;155(4):700–6.

    Article  CAS  PubMed  Google Scholar 

  42. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol. 2001;7(2):73–7.

    Article  CAS  PubMed  Google Scholar 

  43. Lehmann P, Zheng P, Lavker RM, Kligman AM. Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol. 1983;81(2):169–76.

    Article  CAS  PubMed  Google Scholar 

  44. Snyder DS, Greenberg RA. Radiographic measurement of topical corticosteroid-induced atrophy. J Invest Dermatol. 1977;69(3):279–81.

    Article  CAS  PubMed  Google Scholar 

  45. Dykes PJ, Marks R. Measurement of skin thickness: a comparison of two in vivo techniques with a conventional histometric method. J Invest Dermatol. 1977;69(3):275–8.

    Article  CAS  PubMed  Google Scholar 

  46. Marks R. Methods for the assessment of skin atrophogenicity of topical corticosteroids. Dermatologica. 1976;152(Suppl 1):117–26.

    Article  CAS  PubMed  Google Scholar 

  47. Marks R, Dykes PJ, Roberts E. The measurement of corticosteroid induced dermal atrophy by a radiological method. Arch Dermatol Res. 1975;253(2):93–6.

    Article  CAS  PubMed  Google Scholar 

  48. Frosch PJ, Behrenbeck EM, Frosch K, Macher E. The Duhring chamber assay for corticosteroid atrophy. Br J Dermatol. 1981;104(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  49. Andres P, Poncet M, Farzaneh S, Soto P. Short-term safety assessment of clobetasol propionate 0.05 % shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol. 2006;5(4):328–32.

    PubMed  Google Scholar 

  50. Warrenfeltz A, Graham IW. Avulsion injuries in patients receiving corticosteroids. Am Fam Physician. 1975;11(6):74–81.

    CAS  PubMed  Google Scholar 

  51. Stern R, Maibach HI. Hyaluronan in skin: aspects of aging and its pharmacologic modulation. Clin Dermatol. 2008;26(2):106–22.

    Article  PubMed  Google Scholar 

  52. Farage MA, Miller KW, Elsner P, Maibach HI. Intrinsic and extrinsic factors in skin ageing: a review. Int J Cosmet Sci. 2008;30(2):87–95.

    Article  CAS  PubMed  Google Scholar 

  53. Naylor EC, Watson RE, Sherratt MJ. Molecular aspects of skin ageing. Maturitas. 2011;69(3):249–56.

    Article  CAS  PubMed  Google Scholar 

  54. Pels R, Sterry W, Lademann J. Clobetasol propionate: where, when, why? Drugs Today (Barc). 2008;44(7):547–57.

    Article  CAS  PubMed  Google Scholar 

  55. Belge K, Bruck J, Ghoreschi K. Advances in treating psoriasis. F1000Prime Rep. 2014;6:4.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Munro DD, Wilson L. Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy. Br Med J. 1975;3(5984):626–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Herz G, Yawalkar SJ, Weirich EG. Evaluation of halometasone ointment in the treatment of paediatric patients with chronic eczematous dermatoses. J Int Med Res. 1983;11(Suppl 1):21–5.

    PubMed  Google Scholar 

  58. Yawalkar SJ, Macarol V, Montanari C. An overview of international clinical trials with halometasone cream. J Int Med Res. 1983;11(Suppl 1):1–7.

    PubMed  Google Scholar 

  59. Maloney JM, Morman MR, Stewart DM, Tharp MD, Brown JJ, Rajagopalan R. Clobetasol propionate emollient 0.05 % in the treatment of atopic dermatitis. Int J Dermatol. 1998;37(2):142–4.

    Article  CAS  PubMed  Google Scholar 

  60. Rosso JQ, Bhambri S. Daily application of fluocinonide 0.1 % cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol. 2009;2(9):24–32.

    PubMed Central  PubMed  Google Scholar 

  61. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25(6 Pt 2):1166–9.

    Article  CAS  PubMed  Google Scholar 

  62. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1 % tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152(6):1282–9.

    Article  CAS  PubMed  Google Scholar 

  63. Guzzo CA, Weiss JS, Mogavero HS, Ellis CN, Zaias N, Lowe NJ, et al. A review of two controlled multicenter trials comparing 0.05 % halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol. 1991;25(6 Pt 2):1179–83.

    Article  CAS  PubMed  Google Scholar 

  64. Kirkup ME, Birchall NM, Weinberg EG, Helm K, Kennedy CT. Acute and maintenance treatment of atopic dermatitis in children—two comparative studies with fluticasone propionate (0.05 %) cream. J Dermatolog Treat. 2003;14(3):141–8.

    Article  CAS  PubMed  Google Scholar 

  65. Tan MH, Meador SL, Singer G, Lebwohl MG. An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005 %, in patients with atopic dermatitis of the face and intertriginous areas. Int J Dermatol. 2002;41(11):804–9.

    Article  CAS  PubMed  Google Scholar 

  66. Nakagawa H. Comparison of the efficacy and safety of 0.1 % tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan. Clin Drug Investig. 2006;26(5):235–46.

    Article  CAS  PubMed  Google Scholar 

  67. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1 % vs. betamethasone 17-valerate 0.1 % cream in the treatment of seborrhoeic dermatitis: a randomized open-label clinical trial. Br J Dermatol. 2004;151(5):1071–5.

    Article  CAS  PubMed  Google Scholar 

  68. Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009;161(1):159–66.

    Article  CAS  PubMed  Google Scholar 

  69. Kragballe K, Austad J, Barnes L, Bibby A, Brassinne M, Cambazard F, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154(6):1155–60.

    Article  CAS  PubMed  Google Scholar 

  70. Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis. 2006;78(5):348–54.

    PubMed  Google Scholar 

  71. Reygagne P, Mrowietz U, Decroix J, De Waard-Van Der Spek FB, Acebes LO, Figueiredo A, et al. Clobetasol propionate shampoo 0.05 % and calcipotriol solution 0.005 %: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat. 2005;16(1):31–6.

    Article  CAS  PubMed  Google Scholar 

  72. Pauporte M, Maibach H, Lowe N, Pugliese M, Friedman DJ, Mendelsohn H, et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat. 2004;15(6):360–4.

    Article  CAS  PubMed  Google Scholar 

  73. Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0.005 % in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol. 2001;44(1):77–82.

    Article  CAS  PubMed  Google Scholar 

  74. Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J, et al. Tazarotene 0.1 % gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4 Pt 1):590–6.

    Article  CAS  PubMed  Google Scholar 

  75. Breneman DL, Davis M, Berger V, Chaney R. A double-blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis. J Dermatol Treat. 1992;3(1):19–21.

    Article  Google Scholar 

  76. Katz HI, Gross E, Buxman M, Prawer SE, Schwartzel EH, Gibson JR. A double-blind, vehicle-controlled paired comparison of halobetasol propionate cream on patients with plaque psoriasis. J Am Acad Dermatol. 1991;25(6 Pt 2):1175–8.

    Article  CAS  PubMed  Google Scholar 

  77. Bjerke JR, Gjertsen BT, Peterson LE. Prednicarbate (Dermatop™) compared with desoximethasone (Ibaril™): a double-blind clinical trial of a non-halogenated corticosteroid in 57 patients with psoriasis. Clin Trials J. 1990;27(2):94–9.

    Google Scholar 

  78. Terra JB, Potze WJ, Jonkman MF. Whole body application of a potent topical corticosteroid for bullous pemphigoid. J Eur Acad Dermatol Venereol. 2014;28(6):712–8.

    Article  CAS  PubMed  Google Scholar 

  79. Joly P, Roujeau JC, Benichou J, Delaporte E, D’Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681–7.

    Article  CAS  PubMed  Google Scholar 

  80. Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V, et al. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008;21(Suppl 1):S20–6.

    Article  PubMed  Google Scholar 

  81. Kwon HB, Choi Y, Kim HJ, Lee AY. The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: a placebo-controlled, paired-comparison, left-right study. J Drugs Dermatol. 2013;12(4):e63–7.

    PubMed  Google Scholar 

  82. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998;134(8):949–54.

    Article  CAS  PubMed  Google Scholar 

  83. Kragballe K, Larsen FG. A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pustulosis. Acta Derm Venereol. 1991;71(6):540–2.

    CAS  PubMed  Google Scholar 

  84. Hoon TS. A randomized controlled trial to compare calcipotriol with betamethasone valerate for the treatment of cutaneous lichen planus. J Dermatolog Treat. 2004;15(3):141–5.

    Article  Google Scholar 

  85. Kaidbey K, Kopper SC, Sefton J, Gibson JR. A pilot study to determine the effect of tazarotene gel 0.1 % on steroid-induced epidermal atrophy. Int J Dermatol. 2001;40(7):468–71.

    Article  CAS  PubMed  Google Scholar 

  86. McMichael AJ, Griffiths CE, Talwar HS, Finkel LJ, Rafal ES, Hamilton TA, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol. 1996;135(1):60–4.

    Article  CAS  PubMed  Google Scholar 

  87. Schmied C, Piletta PA, Saurat JH. Treatment of eczema with a mixture of triamcinolone acetonide and retinoic acid: a double-blind study. Dermatology. 1993;187(4):263–7.

    Article  CAS  PubMed  Google Scholar 

  88. Lavker RM, Kaidbey K, Leyden JJ. Effects of topical ammonium lactate on cutaneous atrophy from a potent topical corticosteroid. J Am Acad Dermatol. 1992;26(4):535–44.

    Article  CAS  PubMed  Google Scholar 

  89. Kim JE, Kim B, Kim H, Lee JD, Kim HJ, Choi KY, et al. Retinyl retinoate induces hyaluronan production and less irritation than other retinoids. J Dermatol. 2010;37(5):448–54.

    Article  CAS  PubMed  Google Scholar 

  90. Sorg O, Antille C, Kaya G, Saurat JH. Retinoids in cosmeceuticals. Dermatol Ther. 2006;19(5):289–96.

    Article  PubMed  Google Scholar 

  91. Babamiri K, Nassab R. Cosmeceuticals: the evidence behind the retinoids. Aesthet Surg J. 2010;30(1):74–7.

    Article  PubMed  Google Scholar 

  92. Pasonen-Seppanen SM, Maytin EV, Torronen KJ, Hyttinen JM, Hascall VC, MacCallum DK, et al. All-trans retinoic acid-induced hyaluronan production and hyperplasia are partly mediated by EGFR signaling in epidermal keratinocytes. J Invest Dermatol. 2008;128(4):797–807.

    Article  CAS  PubMed  Google Scholar 

  93. Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB J. 1996;10(9):1002–13.

    CAS  PubMed  Google Scholar 

  94. Tanner JM. The measurement of body fat in man. Proc Nutr Soc. 1959;18:148–55.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Professor Jean-Hilaire Saurat for revising the manuscript. This work was conducted as part of dissertation work for the DAS Management of Clinical Trials, University Hospital and Faculty of Medicine, Geneva, Switzerland.

Funding

No funding was received for this work.

Conflict of interest

Laurent Barnes, Gürkan Kaya and Victoria Rollason declare they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Dermatology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland

    Laurent Barnes & Gurkan Kaya

  2. Division of Clinical Pharmacology and Toxicology, University Hospital of Geneva, University of Geneva, Geneva, Switzerland

    Victoria Rollason

Authors
  1. Laurent Barnes
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Gurkan Kaya
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Victoria Rollason
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Laurent Barnes.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 570 kb)

Supplementary material 2 (PDF 22 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barnes, L., Kaya, G. & Rollason, V. Topical Corticosteroid-Induced Skin Atrophy: A Comprehensive Review. Drug Saf 38, 493–509 (2015). https://doi.org/10.1007/s40264-015-0287-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-015-0287-7

Keywords